Lonza

Amaxa® Mouse B Cell Nucleofector® Kit

For Stimulated Mouse B Cells

Cells derived from mouse spleen (mice strain BALB/c and C57BL/6); small round cells; suspension

Note This Kit is NOT suited for unstimulated B cells.

Example for Nucleofection® of stimulated mouse B cells



Mouse B cells were transfected using the Mouse B Cell Nucleofector® Kit. Cells were stimulated with LPS for 24 hours to induce blast formation. Stimulated cells were transfected with program Z-001 and 2 µg of pmaxGFP® Vector. 24 hours post transfection maxGFP® Reporter Protein expression was analyzed by fluorescence microscopy.



Average transfection efficiency and viability of mouse B cells 3 x 10⁶ cells were transfected with program Z-001 using 2 μ g of pmaxGFP® Vector. 24 hours post Nucleofection® cells were analyzed on a Becton Dickinson FACSCalibur[™]. Cell viability was analyzed by using the CellTiter GLO® -Assay [Promega] 24 hours post Nucleofection®.

Product Description

Cat. No.		VPA-1010
Size (Reactions)		25
Mouse B Cell Nucleofector® Solution		2.25 ml (2.05 ml + 10% overfill)
Supplement		0.5 ml (0.45 ml + 10% overfill)
pmaxGFP® Vector (0.5 µg/µl in 10 mM Tris pH 8.0)		30 µg
Certified cuvettes		25
Plastic pipettes		25
Storage and stability	Store Nucleofector® Sol	lution, Supplement and pmaxGFP [®] Vector at 4°C. For long-term storage,
	pmaxGFP® Vector is idea	Ily stored at -20°C. The expiration date is printed on the solution box. Once the
	Nucleofector [®] Suppleme	nt is added to the Nucleofector® Solution it is stable for three months at 4°C.

Required Material

Note

Please make sure that the entire supplement is added to the Nucleofector[®] Solution. The ratio of Nucleofector[®] Solution to supplement is 4.5 : 1. For a single reaction use 82 µl of Nucleofector[®] Solution plus 18 µl of supplement to make 100 µl of total reaction volume.

- Nucleofector[®] Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP[®] Vector
- Substrate of interest, highly purified, preferably by using endotoxin free Kits; A260: A280 ratio should be at least 1.8
- 12-well culture dish or culture system of your choice
- Culture medium I: RPMI1640 [Lonza; Cat. No. 12-167F] supplemented with 10% FCS, 2mM UltraGlutamine I [Lonza, Cat. No. 17-605E/U1], 50 μM β-mercaptoethanol, 1% ITS [Sigma] and LPS (50 μg/ml) if desired
- Culture medium II: RPMI 1640 [Lonza; Cat. No. 12-167F] supplemented with 10% FCS, 2 mM UltraGlutamine I [Lonza, Cat. no. 17-605E/U1], 50μM β-Mercaptoethanol and 50 μg/ml LPS (Sigma)
- For isolation: B cell Isolation Kit, mouse [Milteny; Cat. No. 130-090-862; negative selection]; PBS/ BSA
- Prewarm appropriate volume of culture medium I to 37°C (1 ml per sample)
- Appropriate number of cells (3 x 10⁶ cells per sample); lower or higher cell numbers may influence transfection results

1. Pre Nucleofection®

Note Transfection results may be strain dependent.

Preparation and stimulation of mouse B cells

This section provides an outline for the isolation and cell culture of primary mouse B cells. For further details we recommend the established preparation and cultivation protocols described in literature (e.g. Lymphocytes, A practical approach, Rowland-Jones S. L. and McMichael A.J., Oxford University Press)

- 1.1 Isolate mouse lymphocytes from spleens of 8 11 weeks old mice in cold PBS/BSA. Avoid the erythrocyte lysis step
- 1.2 Purify and enrich the B cells by using the Miltenyi B Cell Isolation Kit. Do not overload the Miltenyi separation separation columns. As a rule of thumb use only 1 column to separate the B cells isolated from 2 spleens
- 1.3 After isolation of pure B cells (around 95%) incubate the cells for 24 hours in culture medium II. Use a culture flask for suspension cells (1 x 10⁸ cells per / T75 flask /20 ml) and cultivate the cells in a humidified 37°C/5% CO₂ incubator. After incubation with LPS the B cells should have formed visible clusters, showing the blast formation has been induced successfully

2

2. Nucleofection®

One Nucleofection® Sample contains

3 x 10 ⁶ cells	
2 µg plasmid DNA (in 1	– 5 μ I H ₂ O or TE) or 2 μ g pmaxGFP [®] Vector or 30 – 300nM siRNA
(3 – 30 pmol/sample)	
100 µl Mouse B Cell Nu	cleofector® Solution

- 2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution
- 2.2 Prepare 12-well plates by filling appropriate number of wells with 1ml of supplemented culture medium l and pre-incubate/equilibrate plates in a humidified 37°C/5% CO₂ incubator
- 2.3 Centrifuge the required number of cells (3 x 10⁶ cells per sample) **at 90xg for 10 minutes** at room temperature. Make sure that no residual medium covers the cell pellet
- 2.4 Resuspend the cell pellet carefully in 100 μl room temperature Nucleofector[®] Solution per sample. Avoid storing the cell suspension longer than 15 minutes in Nucleofector[®] Solution, as this may reduce cell viability
- 2.5 Combine 100 μl of cell suspension with 2 μg DNA or pmaxGFP® Vector or 30 300 nM siRNA (3 30 pmol/sample) or other substrates
- 2.6 Transfer cell/DNA suspension into certified cuvette (sample must cover the bottom of the cuvette without air bubbles). Close the cuvette with the cap
- 2.7 Select the appropriate Nucleofector® Program Z-001 (Z-01 for Nucleofector® | Device)
- 2.8 Insert the cuvette with cell/DNA suspension into the Nucleofector® Cuvette Holder and apply the selected program
- 2.9 Take the cuvette out of the holder once the program is finished
- 2.10 Add ~500 µl of the pre-equilibrated culture medium I to the cuvette and gently transfer the sample immediately into the 12-well plate (final volume 1.5 ml media per well/sample). Use the supplied pipettes and avoid repeated aspiration of the sample

3. Post Nucleofection®

3.1 Incubate the cells in humidified 37°C/5% CO_2 incubator until analysis. Gene expression or down regulation, respectively, is often detectable after only 4 – 8 hours

Additional Information

For an up-to-date list of all Nucleofector® References, please refer to: www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

USA/Canada Phone: 800 521 0390 (toll-free) Fax: 301 845 8338 E-mail: scientific.support@lonza.com Europe and Rest of World Phone: +49 221 99199 400 Fax: +49 221 99199 499 E-mail: scientific.support.eu@lonza.com

References:

1. Rowland-Jones S.L. and McMichael A.J., Lymphocytes, A practical approach, Oxford University Press; ISBN-10:0-19-963816-0, ISBN-1. 13: 978-0-19-962816-1; Publication date: December 16, 1999

Lonza Cologne AG 50829 Cologne, Germany

Please note that the Amaxa® Nucleofector® Technology is not intended to be used for diagnostic purposes or for testing or treatment in humans. The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.

Amaxa, Nucleofector, Nucleofection and maxGFP are registered trademarks of the Lonza Cologne AG in Germany and/or U.S. and/or other countries.

Other product and company names mentioned herein are the trademarks of their respective owners.

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

© Copyright 2009, Lonza Cologne AG. All rights reserved DPA-1011 08/09